Taiho Pharmaceutical Co Ltd (Taiho), an Otsuka Holdings Co Ltd subsidiary, concentrates on researching, developing, producing, and marketing pharmaceutical products. The firm produces and sells capsules, tablets, granules, and injections to treat cancer and other illnesses. Taiho runs two segments: the Pharmaceutical Business and the Consumer Healthcare Business. Its portfolio spans development and commercialization of prescription medicines and consumer healthcare offerings. Taiho’s prescription lineup features anticancer therapies including Lonsurf, TS-1, Lytgobi, and Abraxane, plus other medicines such as Arokaris, an antiemetic, and Bilanoa, an antiallergy agent. Its consumer healthcare range includes Tiovita Drink, a vitamin tonic, BUP-4 LADY, a remedy for overactive bladder, and PITAS Sore Throat Troche, a throat lozenge. The company also funds and mentors biotech startups and academic entrepreneurs through two corporate venture capital entities, Taiho Ventures, LLC and Taiho Innovations, LLC. Taiho operates four manufacturing facilities in Tokushima, Kitajima, Saitama, and Inuyama.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Taiho invests substantially in research and development, aiming to deliver innovative, dependable medicines for patients awaiting new treatment options. The company’s core advantage is developing new drugs through its proprietary discovery platforms. Taiho holds an important position in the Otsuka group, especially in oncology, and focuses on therapies for major unmet needs, including cancers with brain metastases and RAS mutations. It is also expanding discovery efforts in immune-related diseases by leveraging technologies developed through its cancer research. Taiho actively seeks global research partnerships and has established a network with biotech ventures and academia to access novel drug-discovery technologies and promising drug seeds, complement internal capabilities, and speed R&D. Its pipeline covers oncology, hematology, and selected non-oncology areas. Oncology programs target FGFR, EGFR, PI3K/AKT, HSP90, multikinase, PD-1/TIGIT, CD73, IAP, and other mechanisms across solid tumors and combination approaches (many in Phase I–II; TAS-115 and TAS6417 in Phase II/III). Hematology includes DNA methyltransferase and MDS/AML programs (Phase I–III). Non-oncology assets address DMD, rheumatoid arthritis, urticaria, and urinary disorders (Phase II–III).